Trials / Terminated
TerminatedNCT01790035
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
A Phase I and Randomized Controlled Phase II Trial of the Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 placebo-controlled trial to determine efficacy of the probiotic LGG for reducing acute treatment related GI toxicity in patients with GI malignancy with phase 1 safety lead-in.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LGG | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-08-19
- Primary completion
- 2017-01-12
- Completion
- 2021-12-12
- First posted
- 2013-02-12
- Last updated
- 2022-03-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01790035. Inclusion in this directory is not an endorsement.